TOP TEN perturbations for NM_000087 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000087
Selected probe(set): 206417_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000087 (206417_at) across 5392 perturbations tested by GENEVESTIGATOR:

transwell differentiation study 1 (TEER plateau) / untreated MCF10A cell sample

Relative Expression (log2-ratio):2.889082
Number of Samples:4 / 3
Experimental transwell differentiation study 1 (TEER plateau)
MCF10A cells were plated onto polyester permeable supports (Transwells) at a density of 10^5 cells/cm^2. Plateau represents those plates with a plateau trans-epithelial electrical resistance (TEER) of 3000-3200 Ohms x cm^2.
Control untreated MCF10A cell sample
MCF10A cells grown to confluency on sterile plastic.

AsPC-1 / BxPC-3

Relative Expression (log2-ratio):2.8570557
Number of Samples:3 / 3
Experimental AsPC-1
Human xenograft derived metastatic cancer cell line derived from mouse xenografts initiated with metastatic cells from the ascites derived from a 62 years old female Caucasian patient with pancreatic adenocarcinoma. Synonyms:AsPc-1; Aspc-1; ASPC-1; As-PC1; ASPC1; AsPC1; Aspc1; AsPc1 Cellosaurus code:
Control BxPC-3
Human pancreatic adenocarcinoma cell line derived from a 61 years old female patient. Synonyms:BxPc-3; BXPC-3; Bx-PC3; BXPC3; BxPC3; BxPc3 Cellosaurus code:

transwell differentiation study 1 (TEER mid) / untreated MCF10A cell sample

Relative Expression (log2-ratio):2.7188845
Number of Samples:3 / 3
Experimental transwell differentiation study 1 (TEER mid)
MCF10A cells were plated onto polyester permeable supports (Transwells) at a density of 10^5 cells/cm^2. Midpoint represents those plates with a mid trans-epithelial electrical resistance (TEER) of 1400-1600 Ohms x cm^2.
Control untreated MCF10A cell sample
MCF10A cells grown to confluency on sterile plastic.

monocyte activation study 1 (NOD2L; 24h) / untreated monocyte sample (24h)

Relative Expression (log2-ratio):-2.4876328
Number of Samples:5 / 5
Experimental monocyte activation study 1 (NOD2L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) induces preferentially monocyte differentiation into dendritic cells.
Control untreated monocyte sample (24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and collected after 24 hours for RNA isolation.

monocyte activation study 1 (NOD2L/TLR/1L; 24h) / untreated monocyte sample (24h)

Relative Expression (log2-ratio):-2.4645271
Number of Samples:5 / 5
Experimental monocyte activation study 1 (NOD2L/TLR/1L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L) and 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control untreated monocyte sample (24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and collected after 24 hours for RNA isolation.

transwell differentiation study 1 (TEER base) / untreated MCF10A cell sample

Relative Expression (log2-ratio):2.4634562
Number of Samples:3 / 3
Experimental transwell differentiation study 1 (TEER base)
MCF10A cells were plated onto polyester permeable supports (Transwells) at a density of 10^5 cells/cm^2. Base represents those plates with a low trans-epithelial electrical resistance (TEER) of 200-300 Ohms x cm^2.
Control untreated MCF10A cell sample
MCF10A cells grown to confluency on sterile plastic.

null cell adenoma study 1 / normal pituitary gland tissue

Relative Expression (log2-ratio):2.4559088
Number of Samples:2 / 8
Experimental null cell adenoma study 1
Null cell adenoma biopsy samples recovered during transsphenoidal surgery. The tumors were defined by gonadotropic staining for FSH, LH, or alpha subunit in less than 5-10% of cells. Samples were scanned between 04/6/2004 - 15/4/2005.
Control normal pituitary gland tissue
Biopsy samples of healthy pituitary gland recovered post-mortem during autopsy within 2-18 hours of death. Cause of death were mostly various pulmonary or cardiovascular conditions.

monocyte activation study 1 (TLR/1L; 24h) / untreated monocyte sample (24h)

Relative Expression (log2-ratio):-2.408351
Number of Samples:5 / 5
Experimental monocyte activation study 1 (TLR/1L; 24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml mycobacterial 19-kDa triacylated lipopeptide (TLR2/1 ligand, TLR2/1L). This type of activation is via heterodimeric Toll-like receptor 2 and Toll-like receptor 1 (TLR2/1).
Control untreated monocyte sample (24h)
Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D?sufficient (100 nM) human serum and collected after 24 hours for RNA isolation.

HCC study 3 (area A) / HCC study 3 (area C)

Relative Expression (log2-ratio):-2.2996092
Number of Samples:13 / 24
Experimental HCC study 3 (area A)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the center of the tumor (area A). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control HCC study 3 (area C)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken from the perilesional area of the tumor (area C). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.

HCC study 3 (area A) / HCC study 3 (area D)

Relative Expression (log2-ratio):-2.211071
Number of Samples:13 / 19
Experimental HCC study 3 (area A)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Tumorous sample was taken from the center of the tumor (area A). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.
Control HCC study 3 (area D)
Liver tissue biopsy sample from patients with HBV-associated HCC (hepatocellular carcinoma) after orthotopic liver transplantation (OLT) or partial hepatectomy. Non-tumorous sample was taken in an area 2-3 cm away from the tumor (area D). Patients were positive for hepatitis B surface antigen, antibody to hepatitis B core antigen and antibody to hepatitis B antigen and received antiviral treatment with nucleos(t)ide analogues prior to surgery.